Artificial Intelligence

Sanofi anticipates study results for an arthritis drug repurposed to treat COVID-19 will be availabe imminently, which along with Regeneron is testing the immune-blocking therapy Kevzara in two clinical trials.
An occurrence of chronic disorders such as cancer, anemia, diabetes, autoimmune diseases, kidney failure, rheumatoid arthritis, infectious diseases and deficiency of growth hormones is projected to fuel the global biosimilars industry in the coming years.
The United Kingdom alone expects a 29% rise in the incidence of diabetes by 2025, as well as a doubling of the incidence of arthritis by 2030.
By 2030, total knee replacement is projected to grow by up to 189%, according to the American Academy of Orthopaedic Surgeons, and 90% of people who receive one report less pain from chronic conditions such as arthritis.
Otezla is Celgene's marketed oral drug for psoriasis and psoriatic arthritis that had sales of $1.6 billion in 2018, and that number is rising to $2.5 billion in 2023.
The rheumatoid arthritis and psoriasis markets are largely mature, but could see around $5 billion to $10 billion in expansion.
According to the Centers for Disease Control and Prevention (CDC), around 78 million (26%) US adults aged 18 years or older are projected to have doctor-diagnosed arthritis by 2040.
According to the projections by the CDC, an estimated 78 million people in the U.S. are going to be affected by some form of arthritis by the year 2040.
According to the Centers for Disease Control and Preventions (CDC), 25.9% of the adult population in the US will be diagnosed with Arthritis by 2040.
According to Centers for Disease Prevention and Control (CDC), an estimate of 78.4 million adults aged 18 years or above will have doctor-diagnosed arthritis by 2040 in the U.S., as compared to 54.4 million adults in 2013 to 2015.
In the United States, 54 million adults have some form of doctor-diagnosed arthritis , a number projected to increase to 78 million by 2040.
The world health organization predicts the prevalence of Rheumatoid Arthritis to be between 0.3% and 1% and more common in women and in developed countries.
By 2030 there will be 17 million people in the UK with arthritis and 3 million with cancer.
A class of anti-inflammatory drugs already FDA-approved for rheumatoid arthritis could "purge" the reservoir of infected immune cells in people infected by HIV.
Middle East & Africa will grow at moderate rate in rheumatoid arthritis treatment market owing to factor the treatment cost is high for the disease.
Rheumatoid arthritis treatment market will show immense growth as there is rise in FDA approvals to the rheumatoid arthritis drugs.
The idea of targeting the nervous system to control the immune system could potentially be used to treat conditions such as rheumatoid arthritis, autoimmune disease, cancer.
After further research in mice and, eventually, humans, intestinal microbiota and metabolic signatures could help scientists build a predictive profile for who is likely to develop rheumatoid arthritis and the course the disease will take.
Occupational exposure to textile dust has been shown to more than double the risk of developing rheumatoid arthritis in Malaysian women.
Europe could soon gain a second biosimilar antibody drug for rheumatoid arthritis and other autoimmune diseases.
Don't expect lower-cost copycat versions of blockbuster arthritis drug Humira to become available in the U.S. before 2022-another sign that a fledgling market for knockoffs of biotechnology drugs faces slower growth than some had hoped.
Studies have linked antibiotic use early in life with a modestly increased risk of asthma, inflammatory bowel disease, obesity and rheumatoid arthritis.

See full forecast

Last updated: 09 August 2020